481 results about "Controlled drugs" patented technology

Disclosed are bioluminescent bioreporter integrated circuit devices that detect selected analytes in fluids when implanted in the body of an animal. The device comprises a bioreporter that has been genetically engineered to contain a nucleic acid segment that comprises a cis-activating response element that is responsive to the selected substance operably linked to a gene encoding a bioluminescent reporter polypeptide. In preferred embodiments, the target analyte is glucose, glucagons, or insulin. Exposure of the bioreporter to the target substance causes the response element to up-regulate the nucleic acid sequence encoding the reporter polypeptide to produce a luminescent response that is detected and quantitated. In illustrative embodiments, the bioreporter device is encapsulated on an integrated circuit that is capable of detecting the emitted light, processing the resultant signal, and then remotely reporting the results. Also disclosed are controlled drug delivery systems capable of being directly or indirectly controlled by the detection device that provide drugs such as insulin to the animal in reponse to the amount of target analyte present in the body fluids.

Implantable prosthetic devices are provided for controlled drug delivery, for orthopedic and dental applications. The device may include a prosthetic device body having at least one outer surface area; two or more discrete reservoirs located in spaced apart positions across at least a portion of the outer surface area, the reservoirs formed with an opening at the surface of the device body and extending into the device body; and a release system disposed in the reservoirs which comprises at least one therapeutic or prophylactic agent, wherein following implantation into a patient the therapeutic or prophylactic agent is released in a controlled manner from the reservoirs. The prosthetic device body preferably is a joint prosthesis or part thereof, such as a hip prosthesis, a knee prosthesis, a vertebral or spinal disc prosthesis, or part thereof. Optional reservoir caps may further control release kinetics.

An implantable medical device is provided for controlled drug delivery within the bladder, or other body vesicle. The device may include at least one drug reservoir component comprising a drug; and a vesicle retention frame which comprises an elastic wire having a first end, an opposing second end, and an intermediate region therebetween, wherein the drug reservoir component is attached to the intermediate region of the vesicle retention frame. The retention frame prevents accidental voiding of the device from the bladder, and it preferably has a spring constant selected for the device to effectively stay in the bladder during urination while minimizing the irritation of the bladder.

Medical devices and methods are provided for electrical stimulation of neural tissue and controlled drug delivery to a patient. The device includes an implantable drug delivery module which comprises a plurality of reservoirs, a release system comprising at least one drug contained in each of the reservoirs, and control means for selectively releasing a pharmaceutically effective amount of drug from each reservoir; a neural electrical stimulator which comprises a signal generator connected to at least one stimulation electrode for operable engagement with a neural tissue of the patient; and at least one microcontroller for controlling operational interaction of the drug delivery module and the neural electrical stimulator. The microcontroller may control the signal generator and the control means of the drug delivery module. The device may further include a sensor operable to deliver a signal to the microcontroller, for example to indicate when to deliver electrical stimulation, drug, or both.

Methods and devices are provided for enhancing mass transport through any fibrous tissue capsule that may form around an implanted medical device following implantation. Methods and devices are also provided to enhance vascularization around the implanted device, which also will aid in mass transport to/from the device. The device preferably comprises multiple reservoirs containing (i) a drug formulation for short- or long-term, controlled drug delivery, (ii) sensors for sensing an analyte in the patient, or (iii) a combination thereof.

The present invention provides a stent for delivering drugs to a vessel in a body, including a stent framework with a plurality of reservoirs formed therein, a drug polymer positioned in the reservoirs, and a polymer layer positioned on the drug polymer. The present invention also provides a method of manufacturing a drug-polymer stent and a method of treating a vascular condition using the drug-polymer stent.

Implantable or insertable medical devices are provided, which comprises: (a) a biocompatible polymer; and (b) at least one therapeutic agent selected from an anti-inflammatory agent, an analgesic agent, an anesthetic agent, and an antispasmodic agent. The medical devices are adapted for implantation or insertion at a site associated with pain or discomfort upon implantation or insertion. In many embodiments, the therapeutic will be selected from at least one of (i) ketorolac and pharmaceutically acceptable salts thereof (e.g., ketorolac tromethamine) and (ii) 4-diethylamino-2-butynylphenylcyclohexyl glycolate and pharmaceutically acceptable salts thereof (e.g., oxybutynin chloride). Also provided are uses for the implantable or insertable medical devices, which uses comprise reducing pain or discomfort accompanying the implantation or insertion of such devices. Further uses may comprise reducing microbial buildup along the device. Methods for manufacturing implantable or insertable medical devices are also provided.

A multi solvent drug delivery matrix formation method is used to place layers into a reservoir in a stent in a stepwise manner to achieve extended delivery of water soluble, sensitive, or difficult to deliver drugs. The multi solvent matrix formation method allows the formation of a drug reservoir with a layered morphology in which the mixing between layers is limited to allow the different layers to perform different functions in controlling drug delivery. A stent having a drug delivery matrix includes a first beneficial agent layer affixed to the stent by depositing a first solution of a first polymer and a first solvent, and a second beneficial agent layer affixed to the first beneficial agent layer by depositing a second solution of a second polymer and a second solvent. The second solvent is selected so that the first polymer is substantially insoluble in the second solvent to prevent degradation of the first polymer during deposition of the second polymer. A therapeutic agent is provided in the first beneficial agent layer or the second beneficial agent layer to form a drug delivery matrix.

A delivery device for patient-controlled infusion of a medicament, the delivery device comprising a reservoir for the medicament and a pump having a predetermined delivery dose which is capable of displacing the medicament from the reservoir and delivering it to a patient, wherein the pump comprises a pumping means, a first conduit, capable of restricting flow rate, chosen in conjunction with the delivery dose of the pumping means to define a predetermined maximum dosage rate, said conduit connecting the reservoir to a pumping means, a one-way valve in fluid communication with the first conduit and the pumping means which permits medicament flow into the pumping means but prevents reverse flow, a controlling means, and a second conduit extending from the pumping means and having a distal end through which the medicament may be released, wherein the controlling means: (a) is in fluid communication with the pumping means and the second conduit; (b) opens when pressured within the dose chamber exceeds a predetermined minimum opening pressure for the controlling means; and, (c) is adapted to prevent the reverse flow of medicament and air into the pumping means.

A coated medical device have a drug and a nucleating agent thereon. Also provided are methods of increasing or decreasing the size of drug particles on a coated substrate through the use of nucleating agents to thereby increase or decrease the release rate of the drug from the coated substrate.

Polymeric nanofibers have been developed which are useful in a variety of medical and other applications, such as filtration devices, medical prosthesis, scaffolds for tissue engineering, wound dressings, controlled drug delivery systems, cosmetic skin masks, and protective clothing. These can be formed of any of a variety of different polymers, either non-degradable or degradable. In a preferred embodiment demonstrated in the following examples, nanofibers are formed of biodegradable and non biodegradable polyphosphazenes, their blends with other polyphosphazenes or with organic, inorganic/organometallic polymers as well as composite nanofibers of polyphosphazenes with nanosized particles such as hydroxyapatites.

This invention describes a partially absorbable, fiber-reinforced composite in the form of a ring, or a suture-like thread, with modified terminals for use as a controlled delivery system of at least one bioactive agent, wherein said composite comprising an absorbable fiber construct capable of providing time-dependent mechanical properties of a biostable elastomeric matrix containing an absorbable microparticulate ion-exchanger to modulate the release of the bioactive agent(s) for a desired period(s) of time at a specific biological site; this can be a vaginal canal, peritoneal cavity, scrotum, prostate gland, an ear loop or subcutaneous tissue. Such drug delivery systems can be used for the local administration of at least one bioactive agent, including those used as contraceptive, antimicrobial, anti-inflammatory and/or antiviral agents as well as for cancer treatment.

Compositions and methods for controlling transdermal drug delivery, particularly of amine-functional and basic drugs, comprising a blend of a first silicone-based polymer having a reduced silanol concentration and a second silicone-based polymer have a substantial or high silanol concentration. The blend of such silicone-based polymers, particularly pressure-sensitive silicone adhesives, provides sufficient drug solubility and reduced initial drug delivery onset to permit a prolonged delivery duration at a substantially zero-order rate of delivery.

A care system and associated methods are provided for alleviating patient pain, anxiety and discomfort associated with medical or surgical procedures, the system comprising: at least one patient health monitor device coupled to a patient and generating a signal reflecting at least one physiological condition of the patient; a drug delivery controller supplying one or more drugs to the patient; a memory device storing a safety data set reflecting parameters of the at least one patient physiological condition; and an electronic controller interconnected between the patient health monitor, the drug delivery controller and the safety data set; wherein said electronic controller manages the application of the drugs in accord with the safety data set. In another aspect of the invention, the care system facilitates a procedural physician's safely and efficaciously providing conscious sedation to a patient by additionally providing a consciousness monitoring system which monitors the consciousness of the patient and generates a value representing the level of patient consciousness. Methods for alleviating patient pain and anxiety in accordance with the invention comprise connecting a drug delivery device to a patient, such device having a drug delivery controller supplying one or more drugs and being coupled to an electronic controller; attaching at least one patient health monitor device to the patient; accessing a memory device which stores a safety data set reflecting parameters of at least one patient physiological condition; and delivering the drugs to the patient in accord with the safety data set. In further aspects of the invention, the consciousness monitoring system is an automated consciousness monitoring system which includes patient query and response devices. Additional embodiments of the system and methods are directed to alleviating patient pain or discomfort while enabling safe patient controlled drug delivery in correlation with the monitoring of patient health conditions.

The present invention pertains to aerosols which comprise a first compound which is physiologically active and a second compound which is different from the first compound. Such aerosols may be produced “on demand” and can be used to control drug release, to improve vaporizability, or to reduce, modify or eliminate undesirable taste associated with a drug aerosol. The present invention also pertains to methods for producing such aerosols.

Described herein are systems and methods that integrate the injection of contrast agents with imaging catheters. In an embodiment, an imaging catheter comprises a catheter sheath and an imager, e.g., ultrasound transducer. The imaging catheter further comprises a contrast lumen having one or more exit ports for injecting contrast agent into the patient. The contrast lumen extends along the catheter sheath and may be external to or integrated into the catheter sheath. Preferably, the exit port of the contrast lumen is positioned along the catheter sheath at a relatively short known distance from the imager. The catheter may include multiple contrast lumens for injecting different types of contrast agents. In an embodiment, a synchronizing controller is provided to automatically synchronize the injection of contrast agent with imaging. In another embodiment, drug-filled microbubbles in combination with ultrasound imaging are used to deliver a controlled drug dose to a specific treatment site.

The present invention provides compositions for controlled drug delivery, dosage forms, and processes for producing dosage forms. In a composition aspect of the present invention, a composition including a drug and a ceramic structure is provided. The ceramic structure has either a hollow portion wherein the drug is included in the hollow portion or is a collection of smaller particles bound together.

Described are drug delivery systems incorporating electrospun fibers that comprise and deliver physicochemically diverse drug compounds. Such fibers provide significant advantages in drug agent release, such as adaptability for solid dosage delivery to mucosal tissues. This is in addition to allowing for controlled drug release. Systems and methods for large-scale electrospinning productivity are described, including novel microarchitectures allowing for variable pharmacokinetics in drug release.

Medical device and methods are provided for controlled drug delivery in a cardiac patient. The device includes an implantable drug delivery module comprising reservoirs containing a drug and a control means for selectively releasing an effective amount of drug from each reservoir; one or more electrodes or sensors for cardiac monitoring, stimulation, or both; and a microcontroller for controlling operational interaction of the drug delivery module and the cardiac electrode. The electrodes may comprise ECG monitoring, cardioversion, or cardiac pacing electrodes. A medical device also is provided for controlled delivery of drug to a patient having congestive heart failure, which includes an implantable drug delivery module comprising a natriuretic peptide and a release mechanism for selectively releasing a pharmaceutically effective amount of the natriuretic peptide into the patient; and a microcontroller for controlling the release mechanism, for example, in response to one or more monitored patient parameters.

Nanophase single or multiple layer time release coatings over drugs attached to metal surfaces are described. The coatings are deposited over a drug attached to a porous metal substrate using an atomic plasma deposition procedure. Porosity of the substrate and the number of APD deposited layers controls drug release when the attached drug is exposed to an aqueous medium.

Polymeric nanoaggregate drug-delivery compositions including boron-containing copolymers are described. The drug-delivery compositions may further include a therapeutic agent comprising a nucleic acid, a polynucletide, a peptide, a polypeptide, a protein, a pharmaceutical or any combinations thereof. Methods for making the polymeric nanoaggregate compositions including at least one therapeutic agent (for example, insulin) as well as methods for administration of these compositions to mammals are also set forth. The disclosure also describes compositions and methods for controlled drug delivery. Further, polymeric nanoaggregate boron-containing compositions including insulin and methods for monitoring and regulating blood glucose levels of a mammal are also described. The disclosure also describes methods for treatment and/or control of diabetes mellitus by administering polymeric nanoaggregate boron-containing compositions including insulin to a mammal in need.